Epicardial Adipose Tissue Volume and Attenuation in Acute Ischemic Stroke

Recruiting

• Conditions: Ischemic Stroke
• Interventions: Other: Epicardial adipose tissue volume and attenuation

• Registration Number: NCT05631808
• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Brief Summary

Excessive accumulation or abnormal distribution of adipose tissue is a recognized risk factor for ischemic stroke. However, the impact of overweight or obesity on clinical outcomes of ischemic stroke is uncertain. The proposition of obesity paradox in stroke patients makes secondary prevention ambiguous for patients with ischemic stroke and overweight or obesity. Body mass index (BMI) or abdominal visceral fat area was used to measure obesity in previous studies. Epicardial adipose tissue (EAT) is a unique visceral fat, which has higher expression of proinflammatory genes than subcutaneous fat and abdominal visceral fat. And inflammation is closely related to the prognosis of ischemic stroke. In this study, the investigators assume EAT volume or attenuation evaluated by chest computed tomography (CT) scan might affect the prognosis of patients with acute ischemic stroke (AIS). Patients with the first acute ischemic stroke will be stratified into tertile groups based on EAT volume or attenuation. The primary endpoint measure is the proportion of patients with a favorable recovery of nerve function deficiency assessed by Modified Rankin Scale （mRS≤2） at 90 days after the onset of symptoms. Secondary endpoints include the following: the percentage of functional recovery measured by the Barthel Index (BI) at day 90 after stroke onset, the propotion of clinical improvement (with an improvement of ≥ 4 points on the National Institute of Health Stroke Scale score or the resolution of the neurologic deficit) or neurological deterioration (with a decline by ≥ 4 points in the total National Institute of Health Stroke Scale score) at day 7 after stroke onset, incidence of hemorrhagic transformation and mortality within 7 days of symptom onset.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-11-21
• Study First Submitted QC: 2022-11-21
• Study First Posted: 2022-11-30
• Study Start: 2023-02-06
• Status Verified: 2023-04
• Last Update Submitted: 2023-05-06
• Last Update Posted: 2023-05-09
• Primary Completion: 2024-12-01
• Study Completion: 2025-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patient is between 18 and 80 years of old;
• Acute ischemic stroke（AIS）is diagnosed by brain imaging, and this is the first ischemic stroke event;
• Patient is admitted to hospital within 72 hours after stroke onset;
• Modified Rankin scale score (mRS) ≤2 before onset;
• Patient undergoes chest CT scanning during hospitalization;
• Provision of written informed consent.

Exclusion Criteria

• Pregnant or nursing women;
• Complicated with cerebral hemorrhage showed by cranial CT on admission;
• Patient had brain tumor, intracranial aneurysm, arteriovenous malformation, or cerebral hemorrhage or underwent brain surgery in the past;
• Severe cardiac, liver, pulmonary, or kidney disease, malignancy, severe coagulation dysfunction, and systemic organ dysfunction;
• Failure to accomplish 7-day and 3-month follow up.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Lowest tertile	Epicardial adipose tissue volume and attenuation	Participants with lowest tertile of EAT volume or attenuation among all eligible participants.
Intermediate tertile	Epicardial adipose tissue volume and attenuation	Participants with intermediate tertile of EAT volume or attenuation among all eligible participants.
Highest tertile	Epicardial adipose tissue volume and attenuation	Participants with highest tertile of EAT volume or attenuation among all eligible participants.

Primary Outcome Measures

Name	Time	Method
Modified Rankin scale (mRS)	90 days after stroke onset.	Assess patients' prognosis by the score of modified Rankin Scale. In the mRS, the lowest score is 0, the highest score is 6, and higher scores mean worse outcome. A score of 0 indicates the patients have no symptoms at all, and a score of 6 indicates the patients are dead. In this study, we evaluate patient's outcomes by the following criteria. A favorable outcome is defined as an mRS score of 0 to 2, an excellent outcome is defined as an mRS score of 0 to 1, whereas a poor outcome is defined as mRS\>2.

Secondary Outcome Measures

Name	Time	Method
Barthel Index (BI)	90 days after stroke onset.	The percentage of functional recovery from baseline to 90 days after stroke onset, is measured by the Barthel Index (BI). BI score from 0-100, higher scores mean better outcome. We measure how many patients achieve 95 for the BI.
The change of NIHSS score	7 days after stroke onset.	The percentage of functional recovery or deterioration from baseline to 7 days after stroke onset, is measured by the National Institute of Health Stroke Scale, short for NIHSS. NIHSS score from 0-42, higher scores mean worse outcome. We define early functional improvement as an improvement of ≥ 4 points on the NIHSS or the resolution of the neurologic deficit, and early neurological deterioration as a decline by ≥ 4 points in the total NIHSS score within 7 days of symptom onset.
Mortality	within 7 days of symptom onset	We evaluate early mortality due to any cause within 7 days of symptom onset.
Hemorrhagic transformation	within 7 days of symptom onset	Hemorrhagic transformation is considered present when follow-up MRI or CT scans reveal findings consistent with a newly developed extravasation of blood. Symptomatic intracranial hemorrhage is defined as extravascular blood in the brain confirmed by neuroimaging and is associated with neurological deterioration of ≥ 4 points on the NIHSS.

Trial Locations

Locations (1)

First Affiliated Hospital of Xi'an Jiaotong University; 🇨🇳 Xi'an, Shaanxi, China